Rodriguez-Carmona Ana, Pérez-Fontán Miguel, Garca-Naveiro Rafael, Villaverde Pedro, Peteiro Javier
Division of Nephrology, Hospital Juan Canalejo, A Coruña, Spain.
Am J Kidney Dis. 2004 Jul;44(1):132-45. doi: 10.1053/j.ajkd.2004.03.035.
Fluid and sodium removal rates may not be equivalent in patients undergoing automated peritoneal dialysis (APD) and continuous ambulatory peritoneal dialysis (CAPD). This may influence compared cardiovascular outcomes in both groups.
The authors compared prospectively the time courses of ultrafiltration, sodium removal, and residual renal function (RRF) in a group of incident patients treated with CAPD (n = 53) or APD (n = 51) for at least 1 year (mean follow-up, 28.9 months; range, 13 to 62). The authors analyzed potential effects of these factors on blood pressure (BP) control and cardiovascular morbidity and mortality.
Ultrafiltration and sodium removal rates were consistently lower in APD patients (mean differences, 236 mL/d; P = 0.012, and 36 mmol/d; P = 0.018, respectively, end of first year). Moreover, univariate and multivariate analysis indicated that APD therapy results in a moderate, but significantly faster decline of RRF than CAPD therapy. Analysis of clinical outcomes showed that CAPD (versus APD) therapy or higher ultrafiltration or sodium removal rates were associated with a better time course of systolic, but not diastolic, BP. We were unable to identify PD modality, ultrafiltration, or sodium removal rates as independent predictors of cardiovascular morbidity and mortality.
Ultrafiltration and sodium removal rates are consistently lower in incident APD patients than in their counterparts undergoing CAPD. Moreover, RRF declines faster during APD than during CAPD therapy, although this difference may be partially counteracted by a detrimental effect of ultrafiltration on RRF. Aside from a better control of systolic BP in CAPD patients, these differences do not portend significant cardiovascular consequences during the first years of PD therapy.
在接受自动化腹膜透析(APD)和持续性非卧床腹膜透析(CAPD)的患者中,液体和钠的清除率可能并不相同。这可能会影响两组患者的心血管结局比较。
作者前瞻性地比较了一组接受CAPD(n = 53)或APD(n = 51)治疗至少1年(平均随访28.9个月;范围13至62个月)的初治患者的超滤、钠清除和残余肾功能(RRF)的时间进程。作者分析了这些因素对血压(BP)控制以及心血管发病率和死亡率的潜在影响。
APD患者的超滤率和钠清除率始终较低(第一年年底时平均差异分别为236 mL/d;P = 0.012和36 mmol/d;P = 0.018)。此外,单因素和多因素分析表明,与CAPD治疗相比,APD治疗导致RRF下降适度但明显更快。临床结局分析显示,CAPD(与APD相比)治疗或更高的超滤或钠清除率与收缩压(而非舒张压)的更好时间进程相关。我们无法将腹膜透析方式、超滤或钠清除率确定为心血管发病率和死亡率的独立预测因素。
初治APD患者的超滤率和钠清除率始终低于接受CAPD治疗的患者。此外,APD治疗期间RRF的下降速度比CAPD治疗期间更快,尽管超滤对RRF的有害影响可能会部分抵消这种差异。除了CAPD患者的收缩压控制更好外,这些差异在腹膜透析治疗的头几年不会预示着显著的心血管后果。